Nelarabine activity in acute biphenotypic leukemia.
Alvarado
Yesid
Y
Welch
Mary Alma
MA
Swords
Ronan
R
Bruzzi
John
J
Schlette
Ellen
E
Giles
Francis J
FJ
D000208:Acute Disease; D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage; D001087:Arabinonucleosides / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003907:Dexamethasone / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005434:Flow Cytometry; D006801:Humans; D007938:Leukemia / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D008875:Middle Aged; D010641:Phenotype; D014750:Vincristine / Q000008:administration & dosage
D000970:Antineoplastic Agents; D001087:Arabinonucleosides; D014750:Vincristine; C104457:nelarabine; D003907:Dexamethasone; D004317:Doxorubicin; D003520:Cyclophosphamide